Prostate Cancer Deaths and Incident Cases Among American Indian/Alaska Native Men, 1999-2009

被引:19
作者
Hoffman, Richard M. [1 ,2 ,3 ]
Li, Jun [4 ]
Henderson, Jeffrey A. [5 ]
Ajani, Umed A. [4 ]
Wiggins, Charles [1 ,2 ]
机构
[1] Univ New Mexico, Sch Med, Albuquerque, NM 87131 USA
[2] Univ New Mexico, Ctr Canc, Albuquerque, NM 87131 USA
[3] New Mexico VA Hlth Care Syst, Albuquerque, NM 87108 USA
[4] Ctr Dis Control & Prevent CDC, Atlanta, GA USA
[5] Black Hills Ctr Amer Indian Hlth, Rapid City, SD USA
基金
美国国家卫生研究院;
关键词
ALASKA-NATIVES; RADICAL PROSTATECTOMY; UNITED-STATES; INDIANS; MORTALITY; US; SURVEILLANCE; TRENDS;
D O I
10.2105/AJPH.2013.301690
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Objectives. We linked databases to improve identification of American Indians/Alaska Natives (AI/ANs) in determining prostate cancer death and incidence rates. Methods. We linked prostate cancer mortality and incidence data with Indian Health Service (IHS) patient records; analyses focused on residents of IHS Contract Health Service Delivery Area (CHSDA) counties. We calculated age-adjusted incidence and death rates for AI/AN and White men for 1999 to 2009; men of Hispanic origin were excluded. Results. Prostate cancer death rates were higher for AI/AN men than for White men. Death rates declined for White men (-3.0% per year) but not for AI/AN men. AI/AN men had lower prostate cancer incidence rates than White men. Incidence rates declined among Whites (-2.2% per year) and AI/ANs (-1.9% per year). Conclusions. AI/AN men had higher prostate cancer death rates and lower prostate cancer incidence rates than White men. Disparities in accessing health care could contribute to mortality differences, and incidence differences could be related to lower prostate-specific antigen testing rates among AI/AN men.
引用
收藏
页码:S439 / S445
页数:7
相关论文
共 44 条
[21]  
Fritz A., 2003, International Classification of Diseases for Oncology (ICD-O), V3rd
[22]  
GILLILAND FD, 1994, CANCER, V73, P2192, DOI 10.1002/1097-0142(19940415)73:8<2192::AID-CNCR2820730826>3.0.CO
[23]  
2-Y
[24]  
Gilliland FD, 1996, CANCER EPIDEM BIOMAR, V5, P247
[25]   Prostate Specific Antigen Best Practice Statement: 2009 Update [J].
Greene, Kirsten L. ;
Albertsen, Peter C. ;
Babaian, Richard J. ;
Carter, H. Ballentine ;
Gann, Peter H. ;
Han, Misop ;
Kuban, Deborah Ann ;
Sartor, A. Oliver ;
Stanford, Janet L. ;
Zietman, Anthony ;
Carroll, Peter .
JOURNAL OF UROLOGY, 2009, 182 (05) :2232-2241
[26]  
Hankey BF, 1999, CANCER EPIDEM BIOMAR, V8, P1117
[27]   Prostate cancer incidence among American Indian and Alaska Native men, US, 1999-2004 [J].
Henderson, Jeffrey A. ;
Espey, David K. ;
Jim, Melissa A. ;
German, Robert R. ;
Shaw, Kate M. ;
Hoffman, Richard M. .
CANCER, 2008, 113 (05) :1203-1212
[28]   Randomized trial results did not resolve controversies surrounding prostate cancer screening [J].
Hoffman, Richard M. .
CURRENT OPINION IN UROLOGY, 2010, 20 (03) :189-193
[29]   Permutation tests for joinpoint regression with applications to cancer rates. vol 19, pg 335, 2000) [J].
Kim, HJ ;
Fay, MP ;
Feuer, EJ ;
Medthune, DN .
STATISTICS IN MEDICINE, 2001, 20 (04) :655-655
[30]  
Kim HJ, 2000, STAT MED, V19, P335, DOI 10.1002/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.3.CO